Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Liver Diseases

Free Subscription Articles published in PLoS One Retrieve available abstracts of 321 articles: HTML format

Single Articles

January 2025
1. KANG SJ, Park J, Choi GS, Kim JG, et al
   Effects of maximum dose on local control after stereotactic body radiotherapy for oligometastatic tumors of colorectal cancer.
   PLoS One. 2025;20:e0313438.
   PubMed     Abstract available
   
   
   
2. ZAFAR S, Bai Y, Muhammad SA, Guo J, et al
   Molecular dynamics simulation based prediction of T-cell epitopes for the production of effector molecules for liver cancer immunotherapy.
   PLoS One. 2025;20:e0309049.
   PubMed     Abstract available
   
   
   
3. MOUSSA D, Flores JE, Doyle JS, Ryan M, et al
   Synthesising enablers and barriers to hepatocellular carcinoma surveillance-A systematic review of qualitative findings.
   PLoS One. 2025;20:e0313216.
   PubMed     Abstract available
   
   
   
4. SATO M, Tateishi R, Zohar Y, Sato J, et al
   Retrospective evaluation of a novel ultrasound-based imaging analysis software for predicting radiofrequency ablation areas.
   PLoS One. 2025;20:e0317469.
   PubMed     Abstract available
   
   
   
5. ZHU L, Meng Q, Qian W, Shao W, et al
   LARP3 inhibits the apoptosis of hepatocellular carcinoma via the ROS/PI3K/c-Fos axis.
   PLoS One. 2025;20:e0317454.
   PubMed     Abstract available
   
   
   
6. CELDIR MG, Wehby G, Prakash S, Tanaka T, et al
   July effect in hospitalized cirrhosis patients: A US nationwide study using difference-in-differences analysis.
   PLoS One. 2025;20:e0316445.
   PubMed     Abstract available
   
   
   
7. KIM M, Jun BG, Shin HS, Yi JJ, et al
   Impact of high body mass index on hepatocellular carcinoma risk in chronic liver disease: A population-based prospective cohort study.
   PLoS One. 2025;20:e0316175.
   PubMed     Abstract available
   
   
   
8. YANG L, Pham K, Xi Y, Wu Q, et al
   Exploring Glypican-3 targeted CAR-NK treatment and potential therapy resistance in hepatocellular carcinoma.
   PLoS One. 2025;20:e0317401.
   PubMed     Abstract available
   
   
   
9. DOFFOEL M, Chaffraix F, Chahard A, Gras D, et al
   Prevalence of advanced hepatic fibrosis and individualization of associated risk factors by Bayesian analysis in MASLD patients in French cardio-metabolic health networks.
   PLoS One. 2025;20:e0316158.
   PubMed     Abstract available
   
   
   
10. XING Y, Jia D, Zhu X, Yang J, et al
    Inotodiol induces hepatocellular carcinoma apoptosis by activation of MAPK/ERK pathway.
    PLoS One. 2025;20:e0318450.
    PubMed     Abstract available
    
    
    
11. LI J, Song W, Li J, Cai L, et al
    A clinical study exploring the prediction of microvascular invasion in hepatocellular carcinoma through the use of combined enhanced CT and MRI radiomics.
    PLoS One. 2025;20:e0318232.
    PubMed     Abstract available
    
    
    
12. LI ZQ, Gao YT, Zhao CF, An R, et al
    Antioxidant and anti-inflammatory function of walnut green husk aqueous extract (WNGH-AE) on human hepatocellular carcinoma cells (HepG2) treated with t-BHP.
    PLoS One. 2025;20:e0318005.
    PubMed     Abstract available
    
    
    
13. YU L, Yu P, Cao Y, Cao W, et al
    Mechanism of Radix Bupleuri and Hedysarum Multijugum Maxim drug pairs on liver fibrosis based on network pharmacology, bioinformatics and molecular dynamics simulation.
    PLoS One. 2025;20:e0318336.
    PubMed     Abstract available
    
    
    
14. STRAJHAR P, Berzigotti A, Nilius H, Nagler M, et al
    Estimating the prevalence of adults at risk for advanced hepatic fibrosis using FIB-4 in a Swiss tertiary care hospital.
    PLoS One. 2025;20:e0317629.
    PubMed     Abstract available
    
    
    
15. SCHLEICHER EM, Tuchscher J, Weber M, Galle PR, et al
    Impact of type 2 diabetes mellitus on results in the animal naming test in patients with and without liver cirrhosis.
    PLoS One. 2025;20:e0316490.
    PubMed     Abstract available
    
    
    
16. HASAN MAM, Maniruzzaman M, Huang J, Shin J, et al
    Statistical and machine learning based platform-independent key genes identification for hepatocellular carcinoma.
    PLoS One. 2025;20:e0318215.
    PubMed     Abstract available
    
    
    
17. XUE J, Zhao L, Shao L, Zhang H, et al
    Higher risk of carotid plaque among lean individuals with non-alcoholic fatty liver disease: A retrospective study.
    PLoS One. 2025;20:e0316997.
    PubMed     Abstract available
    
    
    
18. ALAM JM, Riha EN, Ahmed H, Thai HM, et al
    Unique North American isolates of severe metastatic hypervirulent Klebsiella pneumoniae strain infections with hepatic abscesses seen in young patients within Texas.
    PLoS One. 2025;20:e0308305.
    PubMed     Abstract available
    
    
    
19. ALQAHTANI SA, AlAhmed RS, AlOmaim WS, Alghamdi S, et al
    Assessment of ChatGPT-generated medical Arabic responses for patients with metabolic dysfunction-associated steatotic liver disease.
    PLoS One. 2025;20:e0317929.
    PubMed     Abstract available
    
    
    
20. MOHAMMADI M, Hasjim BJ, Balbale SN, Polineni P, et al
    Disease trajectory and competing risks of patients with cirrhosis in the US.
    PLoS One. 2025;20:e0313152.
    PubMed     Abstract available
    
    
    
21. ZHANG H, Liu J, Su D, Bai Z, et al
    Diagnostic of fatty liver using radiomics and deep learning models on non-contrast abdominal CT.
    PLoS One. 2025;20:e0310938.
    PubMed     Abstract available
    
    
    
22. CHO EH, Kim JA, Park MS, Kwon MJ, et al
    Mean platelet volume as a biomarker for liver fibrosis in patients with Non-alcoholic fatty liver disease.
    PLoS One. 2025;20:e0318847.
    PubMed     Abstract available
    
    
    
23. YU L, Xiang Q, Liu L
    Oseltamivir-induced hepatotoxicity: A retrospective analysis of the FDA adverse event reporting system.
    PLoS One. 2025;20:e0314970.
    PubMed     Abstract available
    
    
    
24. WONG KK, Ab Hamid SS
    Multiomics in silico analysis identifies TM4SF4 as a cell surface target in hepatocellular carcinoma.
    PLoS One. 2025;20:e0307048.
    PubMed     Abstract available
    
    
    
25. SHILL MC, Jalal MFB, Shuma ML, Mollick PP, et al
    Gynura procumbens leaf extract-loaded self-microemulsifying drug delivery system offers enhanced protective effects in the hepatorenal organs of the experimental rats.
    PLoS One. 2025;20:e0304435.
    PubMed     Abstract available
    
    
    
26. SKLADANY L, Zilincanova D, Zilincan M, Okapec S, et al
    Hepatic venous pressure gradient in patients with (compensated and decompensated) advanced chronic liver disease - A comparison of metabolic dysfunction-associated steatotic liver disease with alcohol-associated liver disease: A retrospective view.
    PLoS One. 2025;20:e0317287.
    PubMed     Abstract available
    
    
    
27. TEWKESBURY DH, Scott JA, Bright-Thomas RJ, Liong S, et al
    Proof of concept pilot study to assess the utility of magnetic resonance extra-cellular volume quantification to diagnose advanced liver disease in people with Cystic Fibrosis.
    PLoS One. 2025;20:e0318085.
    PubMed     Abstract available
    
    
    
28. BERTRAN L, Capellades J, Abello S, Richart C, et al
    Untargeted lipidomic analysis of metabolic dysfunction-associated steatohepatitis in women with morbid obesity.
    PLoS One. 2025;20:e0318557.
    PubMed     Abstract available
    
    
    
29. TERAMOTO K, Ueda Y, Murai R, Ogasawara K, et al
    A hemoperfusion column selectively adsorbs LAP+ lymphocytes to improve anti-tumor immunity and survival of tumor-bearing rats.
    PLoS One. 2025;20:e0305153.
    PubMed     Abstract available
    
    
    
30. WELCKER K, Schneider MA, Reese T, Ehrenfeld A, et al
    Negative impact of chemotherapy on kinetic growth rate of the future liver remnant if applied following PVE or ALPPS.
    PLoS One. 2025;20:e0307937.
    PubMed     Abstract available
    
    
    
31. ADEYEMI O, Osuntoki A, Magbagbeola O, Abdel Hamid MM, et al
    Evidence for infectious merozoites of Plasmodium falciparum from natural isolates of cultured hepatoma cells infected with sporozoites.
    PLoS One. 2025;20:e0319901.
    PubMed     Abstract available
    
    
    
32. CHEN K, Yang M, Li G, Wang W, et al
    Liver transplantation for NASH-related hepatocellular carcinoma versus non-NASH etiologies of hepatocellular carcinoma: A systematic review and meta-analysis.
    PLoS One. 2025;20:e0317730.
    PubMed     Abstract available
    
    
    
33. LIN L, Xie Y, Lin Z, Lin C, et al
    Machine learning for predicting metabolic-associated fatty liver disease including NHHR: a cross-sectional NHANES study.
    PLoS One. 2025;20:e0319851.
    PubMed     Abstract available
    
    
    
34. GRAPENTINE S, Agarwal P, Dolinsky VW, Bakovic M, et al
    Epigenome-wide methylation analysis shows phosphonoethylamine alleviates aberrant DNA methylation in NASH caused by Pcyt2 deficiency.
    PLoS One. 2025;20:e0320510.
    PubMed     Abstract available
    
    
    
35. MA C, Yang X, Zhang L, Zhang J, et al
    BRCA1 regulates glucose and lipid metabolism in diabetes mellitus with metabolic dysfunction-associated steatotic liver disease via the PI3K/Akt signaling pathway.
    PLoS One. 2025;20:e0318696.
    PubMed     Abstract available
    
    
    
36. MAHMUD S, Ajadee A, Sarker A, Ahmmed R, et al
    Exploring common genomic biomarkers to disclose common drugs for the treatment of colorectal cancer and hepatocellular carcinoma with type-2 diabetes through transcriptomics analysis.
    PLoS One. 2025;20:e0319028.
    PubMed     Abstract available
    
    
    
37. ABUBAKR K, Kennedy C, Al-Tikriti S, O'Higgins AC, et al
    Intrahepatic cholestasis of pregnancy and gestational diabetes: Protocol for a scoping review of associations, risk factors, and outcomes.
    PLoS One. 2025;20:e0300076.
    PubMed     Abstract available
    
    
    
38. TONG W, Qin N, Lu T, Liu L, et al
    Integrating bulk and single-cell RNA sequencing reveals SH3D21 promotes hepatocellular carcinoma progression by activating the PI3K/AKT/mTOR pathway.
    PLoS One. 2025;20:e0302766.
    PubMed     Abstract available
    
    
    
39. JAHAN I, Shuvo AUH, Alimullah M, Rahman ASMN, et al
    Purple potato extract modulates fat metabolizing genes expression, prevents oxidative stress, hepatic steatosis, and attenuates high-fat diet-induced obesity in male rats.
    PLoS One. 2025;20:e0318162.
    PubMed     Abstract available
    
    
    
40. GUO W, Weng T, Song Y
    Association of serum iron status with MASLD and liver fibrosis.
    PLoS One. 2025;20:e0319057.
    PubMed     Abstract available
    
    
    
41. LI Z, Guo H, He H, Wang S, et al
    The relationship between smoking cessation history and significant liver fibrosis among the population with metabolic dysfunction-associated steatotic liver disease in the United States.
    PLoS One. 2025;20:e0320573.
    PubMed     Abstract available
    
    
    
42. DONG Y, Jia R, Jiang Y, Li Q, et al
    SMND-309 activates Nrf2 signaling to alleviate acetaminophen-induced hepatotoxicity and oxidative stress.
    PLoS One. 2025;20:e0310879.
    PubMed     Abstract available
    
    
    
43. HUANG Y, Ao T, Wang Y, Zhen P, et al
    The red blood cell distribution width is associated with all-cause and cardiovascular mortality among individuals with non-alcoholic fatty liver disease.
    PLoS One. 2025;20:e0321789.
    PubMed     Abstract available
    
    
    
44. WANG Q, Chen R, Chen S, Wei B, et al
    Exploring the association between dietary indices and metabolic dysfunction-associated steatotic liver disease: Mediation analysis and evidence from NHANES.
    PLoS One. 2025;20:e0321251.
    PubMed     Abstract available
    
    
    
45. POMEJ K, Frick A, Scheiner B, Balcar L, et al
    Study protocol: Fecal Microbiota Transplant combined with Atezolizumab/Bevacizumab in Patients with Hepatocellular Carcinoma who failed to achieve or maintain objective response to Atezolizumab/Bevacizumab - the FAB-HCC pilot study.
    PLoS One. 2025;20:e0321189.
    PubMed     Abstract available
    
    
    
46. TAKADA H, Osawa L, Komiyama Y, Muraoka M, et al
    Imaging-based assessment of muscles and malnutrition predict prognosis in patients with primary hepatocellular carcinoma.
    PLoS One. 2025;20:e0307458.
    PubMed     Abstract available
    
    
    
47. DENG Z, Pu L, Ma Y, Jiang H, et al
    Identification and functional analysis of five hub lncRNAs associated with oncogenesis of Hepatocellular Carcinoma.
    PLoS One. 2025;20:e0321875.
    PubMed     Abstract available
    
    
    
48. CRIBBS KA, Baisley WT, Lahue BJ, Peddu P, et al
    Clinical and safety outcomes in unresectable, very early and early-stage hepatocellular carcinoma following Irreversible Electroporation (IRE) and Transarterial Chemoembolization (TACE): A systematic literature review and meta-analysis.
    PLoS One. 2025;20:e0322113.
    PubMed     Abstract available
    
    
    
49. FICHTNER UA, Maun A, Farin-Glattacker E
    Predictors for psychosocial consequences of screening for liver diseases: A data-driven approach.
    PLoS One. 2025;20:e0319488.
    PubMed     Abstract available
    
    
    
50. ELIAS TP, Shewaye AB, Fisseha H, Nur AM, et al
    Predictors of in-hospital mortality among cirrhotic patients in Ethiopia: A multicenter retrospective study.
    PLoS One. 2025;20:e0322532.
    PubMed     Abstract available
    
    
    
51. ALTAF A, Kiran A, Sarwar M, Maqbool T, et al
    Therapeutic potential of Bacopa monnieri extracts against hepatocellular carcinoma through in-vitro and computational studies.
    PLoS One. 2025;20:e0321445.
    PubMed     Abstract available
    
    
    
52. HU R, Tran B, Li S, Stackpole ML, et al
    Noninvasive prognostication of hepatocellular carcinoma based on cell-free DNA methylation.
    PLoS One. 2025;20:e0321736.
    PubMed     Abstract available
    
    
    
53. KIM Y, Yeuni Y, Heo HJ, Kim ES, et al
    Solute carrier family 2 member 2 (glucose transporter 2): a common factor of hepatocyte and hepatocellular carcinoma differentiation.
    PLoS One. 2025;20:e0321020.
    PubMed     Abstract available
    
    
    
54. HJORTH M, Forsberg A
    Predictive factors for limited health literacy among persons with cirrhosis: A Swedish explorative cross-sectional study.
    PLoS One. 2025;20:e0321780.
    PubMed     Abstract available
    
    
    
55. YANG J, Zhou Z
    Analysis and study of risk factors related to the progression of non-alcoholic fatty liver disease: A retrospective cohort study.
    PLoS One. 2025;20:e0322990.
    PubMed     Abstract available
    
    
    
56. XIE L, Huang L, Fang X, Zha J, et al
    Assessing Liver Function in Rat Models of Acute Liver Failure Using Single-Photon Emission Computed Tomography and Cytokine Levels.
    PLoS One. 2025;20:e0323531.
    PubMed     Abstract available
    
    
    
57. HOU W, Zou T, Yan Y, Zhuang Y, et al
    5-O-Methylvisammioside inhibits HMGB1-induced Angiogenesis of hepatocellular carcinoma through RAGE/MEK/ERK signaling pathway.
    PLoS One. 2025;20:e0322056.
    PubMed     Abstract available
    
    
    
58. ZHANG Y, Zhang H, Liu L
    Integration of single-cell and bulk RNA sequencing identifies and validates T cell-related prognostic model in hepatocellular carcinoma.
    PLoS One. 2025;20:e0322706.
    PubMed     Abstract available
    
    
    
59. TAKADA H, Osawa L, Komiyama Y, Muraoka M, et al
    Serum interferon-gamma-induced protein 10 levels can help predict sarcopenia development in patients with primary hepatocellular carcinoma: A retrospective cohort study.
    PLoS One. 2025;20:e0309852.
    PubMed     Abstract available
    
    
    
60. NGAMSANGIAM W, Techa-Ay S, Sa-Ngiamwibool P, Watcharadetwittaya S, et al
    Distinct chromosome abnormality patterns for differential diagnosis of hepatocellular carcinoma and cholangiocarcinoma.
    PLoS One. 2025;20:e0322408.
    PubMed     Abstract available
    
    
    
61. SATTARI M, Shahaboddin ME, Akhavan Taheri M, Khalili E, et al
    Therapeutic potential of fisetin in hepatic steatosis: Insights into autophagy pathway regulation and endoplasmic reticulum stress alleviation in high-fat diet-fed mice.
    PLoS One. 2025;20:e0322335.
    PubMed     Abstract available
    
    
    
62. HUANG M, Li D, Xia Z, Liao S, et al
    Silencing NRF2 enhances arsenic trioxide-induced ferroptosis in hepatocellular carcinoma cells.
    PLoS One. 2025;20:e0322746.
    PubMed     Abstract available
    
    
    
63. CAO B, Zhou J, Xia B, Li X, et al
    Therapeutic potential of a choline-zinc-vitamin E nutraceutical complex in ameliorating thioacetamide-induced nonalcoholic fatty liver pathology in zebrafish.
    PLoS One. 2025;20:e0324164.
    PubMed     Abstract available
    
    
    
64. PARK S, Rim CH, Jung YK, Yim HJ, et al
    Predictability of clinical outcomes after external beam radiotherapy for hepatocellular carcinoma according to tumor marker dynamics.
    PLoS One. 2025;20:e0323450.
    PubMed     Abstract available
    
    
    
65. HU Y, Zhang X, Xiao Y, Wu Z, et al
    Efficacy and safety of rifaximin in preventing hepatic encephalopathy: A systematic review and meta-analysis.
    PLoS One. 2025;20:e0323359.
    PubMed     Abstract available
    
    
    
66. HE Y, Chang Y, Liu X, Li Y, et al
    Associations of flavonoid intakes with metabolic dysfunction-associated steatotic liver disease in US adults.
    PLoS One. 2025;20:e0322797.
    PubMed     Abstract available
    
    
    
67. LU Y, Lin J, Lu Y, Lin L, et al
    Hepatotoxicity of ICI monotherapy or combination therapy in HCC: A systematic review and meta-analysis.
    PLoS One. 2025;20:e0323023.
    PubMed     Abstract available
    
    
    
68. JIANG H, Qin C, Xu YM
    Feasibility of shear wave elastography for assessing steatosis in early-stage non-alcoholic fatty liver disease.
    PLoS One. 2025;20:e0324637.
    PubMed     Abstract available
    
    
    
69. ZHAO K, Hu HT, Li HL, Cheng HT, et al
    Analysis of the efficacy of splenic artery superselective embolization in cirrhosis with hepatocellular carcinoma.
    PLoS One. 2025;20:e0323829.
    PubMed     Abstract available
    
    
    
70. MA J, Xu R, Li R, Fu Y, et al
    Integration of bioinformatics and identification of the role of m6A genes in NAFLD.
    PLoS One. 2025;20:e0321757.
    PubMed     Abstract available
    
    
    
71. LU H, Mao Z, Zheng M, Zhang M, et al
    Identification of hub gene for the pathogenic mechanism and diagnosis of MASLD by enhanced bioinformatics analysis and machine learning.
    PLoS One. 2025;20:e0324972.
    PubMed     Abstract available
    
    
    
72. BEI X, Zhao C, Liu J, Cao J, et al
    PCYT2 overexpression induces mitochondrial damage and promotes apoptosis in hepatocellular carcinoma cells.
    PLoS One. 2025;20:e0323974.
    PubMed     Abstract available
    
    
    
73. SCHACHTSCHNEIDER KM, Redlon LN, Lokken RP, Huang YH, et al
    Epigenetic regulation of individual components of combined hepatocellular-cholangiocarcinoma.
    PLoS One. 2025;20:e0324145.
    PubMed     Abstract available
    
    
    
74. WEI W, Gan Y, Zhang X, Chen Y, et al
    Exploring the level of metabolic reprogramming and the role of prognostic factor SF3A3 in hepatocellular carcinoma through integrated single-cell landscape analysis.
    PLoS One. 2025;20:e0323559.
    PubMed     Abstract available
    
    
    
75. ESSAM MYN, Kouam AF, Fepa AGK, Seukep AJ, et al
    Serological evidence and factors associated to liver damage in malaria-typhoid infected patients consulting in two health facilities, Yaounde-Cameroon.
    PLoS One. 2025;20:e0319547.
    PubMed     Abstract available
    
    
    
76. ORRIOLS G, Aljama C, Rodriguez-Frias F, Medina PG, et al
    Quantification of serum elastase inhibitory activity in patients with pulmonary emphysema with and without alpha-1 antitrypsin deficiency.
    PLoS One. 2025;20:e0324237.
    PubMed     Abstract available
    
    
    
77. MARGULIES BS, Likhitpanichkul M, Tripathy D
    Reshaping the landscape of locoregional treatments for breast cancer liver metastases: A novel, intratumoral, p21-targeted percutaneous therapy increases survival in BALB/c mice inoculated with 4T1 triple negative breast cancer cells in the liver.
    PLoS One. 2025;20:e0323621.
    PubMed     Abstract available
    
    
    
78. LEE CW, Kang ES, Jeong S, Han HW, et al
    Identification of potentially effective drugs for metabolic dysfunction-associated steatotic liver disease against liver cirrhosis: In-silico drug repositioning-based retrospective cohort study.
    PLoS One. 2025;20:e0323880.
    PubMed     Abstract available
    
    
    
79. WEI B, Zheng Y, Yu S, Wang A, et al
    Identification of key genes and signaling pathways of liver cancer and model construction for prognosis and diagnosis based on bioinformatics analysis.
    PLoS One. 2025;20:e0325610.
    PubMed     Abstract available
    
    
    
80. WU C, Chen X, Zhang Y, Du Y, et al
    A novel ferroptosis-related signature for predicting prognosis, immune characteristics, and treatment prediction in hepatocellular carcinoma.
    PLoS One. 2025;20:e0322158.
    PubMed     Abstract available
    
    
    
81. YOO HW, Yang CJ, Yoo JJ, Chang Y, et al
    Diagnostic performance of microvascular flow imaging for noninvasive assessment of liver fibrosis in chronic liver disease.
    PLoS One. 2025;20:e0322102.
    PubMed     Abstract available
    
    
    
82. GRAF M, Graf C, Ziegelmayer S, Marka AW, et al
    Complications of image-guided liver biopsies: Results of a nationwide database analysis.
    PLoS One. 2025;20:e0323695.
    PubMed     Abstract available
    
    
    
83. RONG F, Cheng B, Guo L, Zeng S, et al
    Correlation analysis of mitochondrial DNA maintenance-related genes with HCC prognosis, tumor mutation burden and tumor microenvironment features.
    PLoS One. 2025;20:e0325033.
    PubMed     Abstract available
    
    
    
84. YOON J, Lee Y, Yoon S, Sung J, et al
    Deep learning reconstruction of free-breathing, diffusion-weighted imaging of the liver: A comparison with conventional free-breathing acquisition.
    PLoS One. 2025;20:e0320362.
    PubMed     Abstract available
    
    
    
85. FU T, Ling J, Zhao H, Lin K, et al
    Comparative association between NAFLD and MAFLD with cardiovascular events and mortality: Evidence from observational studies.
    PLoS One. 2025;20:e0312650.
    PubMed     Abstract available
    
    
    
86. WANGLER MF, Chao YH, Roth M, Welti R, et al
    Drosophila models uncover substrate channeling effects on phospholipids and sphingolipids in peroxisomal biogenesis disorders.
    PLoS One. 2025;20:e0324143.
    PubMed     Abstract available
    
    
    
87. GRANDT J, Johansen CD, Jensen AH, Werge MP, et al
    The hepatic transcriptome is differentially regulated by a standardized meal in healthy individuals compared to patients with fatty liver disease.
    PLoS One. 2025;20:e0307345.
    PubMed     Abstract available
    
    
    
88. JOE H, Oh JE, Cho YJ, Shin HS, et al
    Association between smoking status and non-alcoholic fatty liver disease.
    PLoS One. 2025;20:e0325305.
    PubMed     Abstract available
    
    
    
89. FELIZARI LD, Bowman SM, Crasto CJ, Sarturi JO, et al
    Hepatic transcriptome profiling unveils candidate genes in cattle with liver abscesses under the influence of beef genetics in dairy cattle.
    PLoS One. 2025;20:e0324209.
    PubMed     Abstract available
    
    
    
90. LI J, Hu Q, Leng J, Zhou B, et al
    Global burden of metabolic-associated fatty liver disease among women of childbearing age: Trends from 1990 to 2021 and projections to 2040.
    PLoS One. 2025;20:e0326244.
    PubMed     Abstract available
    
    
    
91. LIN X, Zhang Z, Lin Y, Lu S, et al
    The effects of rifaximin and lactulose on the gut-liver-brain axis in rats with minimal hepatic encephalopathy.
    PLoS One. 2025;20:e0325988.
    PubMed     Abstract available
    
    
    
92. LIU W, Gao J, Ren S, Nashun B, et al
    Drug repositioning for pan-cancers of the digestive system: Identification of amonafide and BX795 as potential therapeutics via integrative Omics analysis.
    PLoS One. 2025;20:e0325700.
    PubMed     Abstract available
    
    
    
93. ZHONG J, Li Y, Liu Y, Qiao J, et al
    Hepatitis B virus X protein (HBx)-mediated immune modulation and prognostic model development in hepatocellular carcinoma.
    PLoS One. 2025;20:e0325363.
    PubMed     Abstract available
    
    
    
94. BAE JH, Lee MJ, Kim SH, Kim JY, et al
    Fatty liver index and risk of type 2 diabetes of adults with normoglycemia: Insights into insulin sensitivity and beta-cell function.
    PLoS One. 2025;20:e0327058.
    PubMed     Abstract available
    
    
    
95. ABDELHAMEED MF, El-Baset MA, Khattab AR, Taher RF, et al
    Hepatoprotective action of Sonchus oleraceus against paracetamol-induced toxicity via Nrf2/KEAP-1/HO-1 pathway in relation to its metabolite fingerprint and in silico studies.
    PLoS One. 2025;20:e0325782.
    PubMed     Abstract available
    
    
    
96. BUTTLER L, Tiede A, Griemsmann M, Rieland H, et al
    Differences in the incidence of cirrhosis-associated complications between MASLD, MetALD and ALD among patients with decompensated liver cirrhosis.
    PLoS One. 2025;20:e0325673.
    PubMed     Abstract available
    
    
    
97. TOWNSEND J, Alluhibi R, Lynch N, Woolf R, et al
    Alpha-1 Antitrypsin Deficiency-Associated panniculitis: A survey of lived experience.
    PLoS One. 2025;20:e0326686.
    PubMed     Abstract available
    
    
    
98. HUANG S, Hu W, Fang T
    The global impact of non-alcoholic fatty liver disease (including cirrhosis) in the elderly from 1990 to 2021 and future projections of disease burden.
    PLoS One. 2025;20:e0325961.
    PubMed     Abstract available
    
    
    
99. THEEL W, Brouwer WP, van Rossum E, Apers J, et al
    Evaluation of the prevalence of MASLD, MASH and liver fibrosis in a Dutch bariatric cohort.
    PLoS One. 2025;20:e0324813.
    PubMed     Abstract available
    
    
    
100. AOKI Y, Miki A, Sakuma Y, Watanabe J, et al
     Clinical impact of low bone mineral density in patients with colorectal cancer liver metastasis undergoing hepatectomy.
     PLoS One. 2025;20:e0324719.
     PubMed     Abstract available
     
     
     
101. WEN Y, Min Y, Lei Y, Wei Z, et al
     Cardiometabolic dysfunction burden and mortality outcomes in metabolic dysfunction-associated steatotic liver disease.
     PLoS One. 2025;20:e0327772.
     PubMed     Abstract available
     
     
     
102. SEDDA F, Caddeo A, Sasidharan K, Perra G, et al
     Galectin-3 inhibition ameliorates hepatic steatosis in a multilineage 3D spheroid model.
     PLoS One. 2025;20:e0326373.
     PubMed     Abstract available
     
     
     
103. SHANG C, He T, Zhang Y
     Tumor-associated macrophage-based predictive and prognostic model for hepatocellular carcinoma.
     PLoS One. 2025;20:e0325120.
     PubMed     Abstract available
     
     
     
104. BAZMI S, Parvaneh T, Mohammadi Z, Pishdad P, et al
     Association of prior opium addiction with incident non-alcoholic fatty liver disease: A case-control study.
     PLoS One. 2025;20:e0326889.
     PubMed     Abstract available
     
     
     
105. ALBHAISI S, Robinson A, Alsaadawi R, Sabo RT, et al
     Liver-related outcomes in patients with cirrhosis: The value of clinical and laboratory data and noninvasive tests.
     PLoS One. 2025;20:e0326702.
     PubMed     Abstract available
     
     
     
106. LEE EH, Seo MH, Park SY, Mukherjee S, et al
     A novel yeast-derived aldehyde-reducing compound MF001 protects against alcohol-induced liver damage.
     PLoS One. 2025;20:e0327648.
     PubMed     Abstract available
     
     
     
107. MAO L, Yang H, Huang N, Li Y, et al
     MiR-122 promotes metastasis of hepatoma cells by modulating RBM47-integrin alpha V-TGF-beta signaling.
     PLoS One. 2025;20:e0327915.
     PubMed     Abstract available
     
     
     
108. ZHOU L, Wu B, Bian Y, Lu Y, et al
     Hepatotoxicity associated with statins: A retrospective pharmacovigilance study based on the FAERS database.
     PLoS One. 2025;20:e0327500.
     PubMed     Abstract available
     
     
     
109. AHN J, Kim S, Jeong JY, Heo S, et al
     Whole genome DNA methylation patterns in tissue and cfDNA associated with fibrosis reflect the complex signature of MASLD.
     PLoS One. 2025;20:e0328207.
     PubMed     Abstract available
     
     
     
110. ANANCHUENSOOK P, Piyawannasuth K, Suksawatamnuay S, Thaimai P, et al
     Combination of modified albumin-bilirubin grade and platelet count to predict high-risk varices in patients with hepatocellular carcinoma.
     PLoS One. 2025;20:e0327967.
     PubMed     Abstract available
     
     
     
111. LEE D, Shim SH, Kang KS
     Protopanaxadiol stimulates glucose consumption by modulating the AMP-activated protein kinase pathway in myotubes, hepatoma cells, and adipocytes.
     PLoS One. 2025;20:e0328486.
     PubMed     Abstract available
     
     
     
112. NASIR M, Xu Y, Hasenstab K, Yechoor A, et al
     Liver MRI proton density fat fraction inference from contrast enhanced CT images using deep learning: A proof-of-concept study.
     PLoS One. 2025;20:e0328867.
     PubMed     Abstract available
     
     
     
113. RIVADENEIRA J, Fuenmayor-Gonzalez L, Hasnaoui A, Ortiz D, et al
     Prognostic factors associated with recurrence in patients undergoing surgery for hepatic cystic echinococcosis: A systematic review protocol.
     PLoS One. 2025;20:e0329235.
     PubMed     Abstract available
     
     
     
114. BOUSHEHRI YG, Meymanatabadi Z, Tanha AE, Azami P, et al
     Association of triglyceride glucose-body mass index (TyG-BMI) with metabolic dysfunction-associated steatotic liver disease: A systematic review and meta-analysis.
     PLoS One. 2025;20:e0324483.
     PubMed     Abstract available
     
     
     
115. MULLER L, Kloeckner R, Heim L, Moos M, et al
     Bone mineral density predicts survival in patients with hepatocellular carcinoma and portal vein tumor thrombosis.
     PLoS One. 2025;20:e0330336.
     PubMed     Abstract available
     
     
     
116. MAO Y, Du J, Li B, Wang J, et al
     Global burden of NAFLD 1990-2021 and projections to 2035: Results from the Global Burden of Disease study 2021.
     PLoS One. 2025;20:e0330504.
     PubMed     Abstract available
     
     
     
117. LIU Y, Shao Y, Zhu X, Shen Z, et al
     Mitochondrial proteins: Potential pathophysiological mechanisms of malignant progression in HCC.
     PLoS One. 2025;20:e0329209.
     PubMed     Abstract available
     
     
     
118. ABLAYEVA A, Syssoyev D, Akhmedullin R, Beyembetova A, et al
     Epidemiology of liver cancer in Kazakhstan: data from the Unified National Electronic Health System, 2014-2023.
     PLoS One. 2025;20:e0330423.
     PubMed     Abstract available
     
     
     
119. QIN H, Chen R, Xie Y, Liu H, et al
     Kummerowia striata extract protects paracetamol-induced liver injury by modulating the S1P/Nrf2/Keap1 pathway.
     PLoS One. 2025;20:e0329837.
     PubMed     Abstract available
     
     
     
120. CHEN N, Zang B, Chen Y
     Predicting one-year post-surgical recurrence in colorectal liver metastasis using CT radiomics and machine learning.
     PLoS One. 2025;20:e0330828.
     PubMed     Abstract available
     
     
     
121. EL ATIFI W, El Rhazouani O, Khan FM, Sekkat H, et al
     Optimizing ensemble machine learning models for accurate liver disease prediction in healthcare.
     PLoS One. 2025;20:e0330899.
     PubMed     Abstract available
     
     
     
122. SUCULARLI C
     Machine learning-based identification of diagnostic and prognostic mitotic cell cycle genes in hepatocellular carcinoma.
     PLoS One. 2025;20:e0331118.
     PubMed     Abstract available
     
     
     
123. AHMED RF, Elgamal AM, El-Nashar HAS, Mowaad NA, et al
     Phenolic-rich extracts of Teucrium oliverianum confer protection against thioacetamide-induced liver fibrosis in rats: Insights from metabolomics, biochemical and histopathological analysis.
     PLoS One. 2025;20:e0330595.
     PubMed     Abstract available
     
     
     
124. ZHU J, Chen Y, Han Y, Li J, et al
     Mechanism of Huanglian Wendan Decoction in ameliorating non-alcoholic fatty liver disease via modulating gut microbiota-mediated metabolic reprogramming and activating the LKB1/AMPK pathway.
     PLoS One. 2025;20:e0331303.
     PubMed     Abstract available
     
     
     
125. THEUNE LE, Ghoreishi N, Weikert C, Muller-Graf C, et al
     Characteristics of a tattooed population and a possible role of tattoos as a risk factor for chronic diseases: Results from the LIFE-Adult-Study.
     PLoS One. 2025;20:e0319229.
     PubMed     Abstract available
     
     
     
126. CHAI L, Zhou Y, Zhou N, Xiao Y, et al
     Machine learning-based prediction model for 28-day mortality in acute kidney injury patients with liver cirrhosis: A MIMIC-IV database analysis.
     PLoS One. 2025;20:e0328662.
     PubMed     Abstract available
     
     
     
127. MULLER-KUHNLE J, Schanz M, Schricker S, Benignus C, et al
     Predicting severe renal dysfunction in alcohol-associated cirrhosis: Comparative performance of liver function scores and machine learning models.
     PLoS One. 2025;20:e0332840.
     PubMed     Abstract available
     
     
     
128. HE Z, Cao J, Yu Y, Peng C, et al
     Role of endothelial cell markers in prognosis of hepatocellular carcinoma: Integrating bioinformatics analysis and experimental validation.
     PLoS One. 2025;20:e0331580.
     PubMed     Abstract available
     
     
     
129. XIE Y, Yang H, Lu S, Long G, et al
     The impact of proximity to major central hepatic vasculature on perioperative outcomes and size-based risk stratification in hepatic hemangioma surgery.
     PLoS One. 2025;20:e0332198.
     PubMed     Abstract available
     
     
     
130. LU X, Wang S, Du Y, Xie B, et al
     KYLO-0603, a novel liver-targeting, thyroid hormone receptor-beta agonist for the inhibition of MASH progression.
     PLoS One. 2025;20:e0331768.
     PubMed     Abstract available
     
     
     
131. XU C, Wang G, Zhang M, Lv L, et al
     Albumin-corrected anion gap as a predictive marker for mortality in critically Ill cirrhosis patients: an analysis based on the MIMIC-IV database.
     PLoS One. 2025;20:e0332490.
     PubMed     Abstract available
     
     
     
132. DU C, Wang H, Cao W, Yu Z, et al
     Perioperative and long-term outcomes of laparoscopic liver resection for combined hepatocellular carcinoma and cholangiocarcinoma versus intrahepatic cholangiocarcinoma: A propensity score matching analysis.
     PLoS One. 2025;20:e0328104.
     PubMed     Abstract available
     
     
     
133. YUAN J, Chen Z, Gu Y, Liang Y, et al
     Effects of alcohol consumption on the prevalence and incidence of non-alcoholic fatty liver disease: A systematic review and meta-analysis.
     PLoS One. 2025;20:e0330105.
     PubMed     Abstract available
     
     
     January 2024
134. NAGY NS, Essawy AE, Al-Sherif SS, Ali MM, et al
     Characterization and biological applications of gonadal extract of Paracentrotus lividus collected along the Mediterranean coast of Alexandria, Egypt.
     PLoS One. 2024;19:e0296312.
     PubMed     Abstract available
     
     
     
135. ORIMOLOYE HT, He D, Li T, Janzen C, et al
     Alpha-1 antitrypsin deficiency and pregnancy complications and birth outcomes: A population-based cohort study in Denmark.
     PLoS One. 2024;19:e0296434.
     PubMed     Abstract available
     
     
     
136. KOGISO T, Takayanagi K, Ishizuka T, Otsuka M, et al
     Serum level of full-length connective tissue growth factor reflects liver fibrosis stage in patients with Fontan-associated liver disease.
     PLoS One. 2024;19:e0296375.
     PubMed     Abstract available
     
     
     
137. NAVARRO-MEZA M, Diaz-Munoz M, Cruz-Ramos JA, Trinidad Gallardo JR, et al
     Hepatocyte ballooning and steatosis in early and late gestation without liver malfunction: Effects of low protein/high carbohydrate diet.
     PLoS One. 2024;19:e0294062.
     PubMed     Abstract available
     
     
     
138. GITTUS M, Moore J, Ong ACM
     Liver transplant recipients with polycystic liver disease have longer waiting times but better long-term clinical outcomes than those with liver disease due to other causes: A retrospective cross-sectional study.
     PLoS One. 2024;19:e0294717.
     PubMed     Abstract available
     
     
     
139. KAI M, Hikita H, Kazuki M, Tahata Y, et al
     Clinical factors associated with the therapeutic efficacy of atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma: A multicenter prospective observational study.
     PLoS One. 2024;19:e0294590.
     PubMed     Abstract available
     
     
     
140. QIANG B, Xu Q, Pan Y, Wang J, et al
     Shear wave elastography: A noninvasive approach for assessing acute kidney injury in critically ill patients.
     PLoS One. 2024;19:e0296411.
     PubMed     Abstract available
     
     
     
141. OLSON JC, Subramanian RM
     Comparative efficacy of terlipressin and norepinephrine for treatment of hepatorenal syndrome-acute kidney injury: A systematic review and meta-analysis.
     PLoS One. 2024;19:e0296690.
     PubMed     Abstract available
     
     
     
142. SATO T, Oishi K
     Time-restricted feeding has a limited effect on hepatic lipid accumulation, inflammation and fibrosis in a choline-deficient high-fat diet-induced murine NASH model.
     PLoS One. 2024;19:e0296950.
     PubMed     Abstract available
     
     
     
143. LAUE T, Junge N, Leiskau C, Mutschler F, et al
     Diminished measles immunity after paediatric liver transplantation-A retrospective, single-centre, cross-sectional analysis.
     PLoS One. 2024;19:e0296653.
     PubMed     Abstract available
     
     
     
144. ELLIS P, Parekh G, Duvoix A, Watson L, et al
     Characteristics of alpha-1 antitrypsin deficiency related lung disease exacerbations using a daily symptom diary and urinary biomarkers.
     PLoS One. 2024;19:e0297125.
     PubMed     Abstract available
     
     
     
145. GUHA S, Ibrahim A, Wu Q, Geng P, et al
     Machine learning-based identification of contrast-enhancement phase of computed tomography scans.
     PLoS One. 2024;19:e0294581.
     PubMed     Abstract available
     
     
     
146. LIU Z, Shao Y, Duan X
     Genetic link between primary biliary cholangitis and connective tissue diseases in European populations: A two-sample Mendelian randomization study.
     PLoS One. 2024;19:e0298225.
     PubMed     Abstract available
     
     
     
147. MATSUO M, Kanbe A, Noguchi K, Niwa A, et al
     Time-course analysis of liver and serum galectin-3 in acute liver injury after alpha-galactosylceramide injection.
     PLoS One. 2024;19:e0298284.
     PubMed     Abstract available
     
     
     
148. NAIRZ J, Messner A, Kiechl SJ, Winder B, et al
     Determinants of non-alcoholic fatty liver disease in young people: Maternal, neonatal, and adolescent factors.
     PLoS One. 2024;19:e0298800.
     PubMed     Abstract available
     
     
     
149. LADNER DP, Gmeiner M, Hasjim BJ, Mazumder N, et al
     Increasing prevalence of cirrhosis among insured adults in the United States, 2012-2018.
     PLoS One. 2024;19:e0298887.
     PubMed     Abstract available
     
     
     
150. ELGUEZABAL RODELO RG, Porchia LM, Torres-Rasgado E, Lopez-Bayghen E, et al
     Visceral and subcutaneous abdominal fat is associated with non-alcoholic fatty liver disease while augmenting Metabolic Syndrome's effect on non-alcoholic fatty liver disease: A cross-sectional study of NHANES 2017-2018.
     PLoS One. 2024;19:e0298662.
     PubMed     Abstract available
     
     
     
151. DUHRING S, Schuster S
     Studying mixed-species biofilms of Candida albicans and Staphylococcus aureus using evolutionary game theory.
     PLoS One. 2024;19:e0297307.
     PubMed     Abstract available
     
     
     
152. CHEN Q, Sun Q, Zhang J, Li B, et al
     Cost-effectiveness analysis of Tislelizumab vs Sorafenib as the first-line treatment of unresectable hepatocellular carcinoma.
     PLoS One. 2024;19:e0295090.
     PubMed     Abstract available
     
     
     
153. STAUFFER WT, Goodman AZ, Bobardt M, Ure DR, et al
     Mice lacking cyclophilin B, but not cyclophilin A, are protected from the development of NASH in a diet and chemical-induced model.
     PLoS One. 2024;19:e0298211.
     PubMed     Abstract available
     
     
     
154. YANG Y, Mirzaei G
     Performance analysis of data resampling on class imbalance and classification techniques on multi-omics data for cancer classification.
     PLoS One. 2024;19:e0293607.
     PubMed     Abstract available
     
     
     
155. LI YS, Xia YG, Liu YL, Jiang WR, et al
     Metabolic-dysfunction associated steatotic liver disease-related diseases, cognition and dementia: A two-sample mendelian randomization study.
     PLoS One. 2024;19:e0297883.
     PubMed     Abstract available
     
     
     
156. MCTEER M, Applegate D, Mesenbrink P, Ratziu V, et al
     Machine learning approaches to enhance diagnosis and staging of patients with MASLD using routinely available clinical information.
     PLoS One. 2024;19:e0299487.
     PubMed     Abstract available
     
     
     
157. NAH EH, Choi YJ, Cho S, Park H, et al
     Changes in nonalcoholic fatty liver disease and M2BPGi due to lifestyle intervention in primary healthcare.
     PLoS One. 2024;19:e0298151.
     PubMed     Abstract available
     
     
     
158. BUDZYNSKA A, Kubik A, Kacperski K, Pastusiak P, et al
     PET/CT and SPECT/CT imaging of 90Y hepatic radioembolization at therapeutic and diagnostic activity levels: Anthropomorphic phantom study.
     PLoS One. 2024;19:e0271711.
     PubMed     Abstract available
     
     
     
159. LI H, Wang C
     MIS-Net: A deep learning-based multi-class segmentation model for CT images.
     PLoS One. 2024;19:e0299970.
     PubMed     Abstract available
     
     
     
160. YAMASHITA T, Suzuki N, Motoyoshi K, Zhu W, et al
     Characteristics of patients with longer treatment period of lenvatinib for unresectable hepatocellular carcinoma: A post-hoc analysis of post-marketing surveillance study in Japan.
     PLoS One. 2024;19:e0298420.
     PubMed     Abstract available
     
     
     
161. KANEKO S, Asahina Y, Murakawa M, Azuma S, et al
     Analysis of prognosis and background liver disease in non-advanced hepatocellular carcinoma in two decades.
     PLoS One. 2024;19:e0297882.
     PubMed     Abstract available
     
     
     
162. YANG X, Wang S, Sun C, Xia Y, et al
     Causal effect of porphyria biomarkers on alcohol-related hepatocellular carcinoma through Mendelian Randomization.
     PLoS One. 2024;19:e0299536.
     PubMed     Abstract available
     
     
     
163. OKUBO T, Atsukawa M, Tsubota A, Ono H, et al
     Low vitamin D levels accelerates muscle mass loss in patients with chronic liver disease.
     PLoS One. 2024;19:e0299313.
     PubMed     Abstract available
     
     
     
164. KIM A, Kang D, Choi SC, Cho J, et al
     Steatotic liver disease and its newly proposed sub-classifications correlate with progression of the coronary artery calcium score.
     PLoS One. 2024;19:e0301126.
     PubMed     Abstract available
     
     
     
165. CHAISUPASAKUL P, Pekthong D, Wangteeraprasert A, Kaewkong W, et al
     Combination of ethyl acetate fraction from Calotropis gigantea stem bark and sorafenib induces apoptosis in HepG2 cells.
     PLoS One. 2024;19:e0300051.
     PubMed     Abstract available
     
     
     
166. SRIPHOOSANAPHAN S, Pantumongkol W, Kulpeng W, Charonpongsuntorn C, et al
     Cost-utility analysis of atezolizumab combined with bevacizumab for unresectable hepatocellular carcinoma in Thailand.
     PLoS One. 2024;19:e0300327.
     PubMed     Abstract available
     
     
     
167. BAGER P, Bossen L, Gantzel R, Gronbaek H, et al
     High-dose oral thiamine versus placebo for chronic fatigue in patients with primary biliary cholangitis: A crossover randomized clinical trial.
     PLoS One. 2024;19:e0301354.
     PubMed     Abstract available
     
     
     
168. CAI W, Qiu T, Hu W, Fang T, et al
     Changes in the intestinal microbiota of individuals with non-alcoholic fatty liver disease based on sequencing: An updated systematic review and meta-analysis.
     PLoS One. 2024;19:e0299946.
     PubMed     Abstract available
     
     
     
169. CHEN R, An Y, Xu M
     Prognostic difference between surgery and external radiation in patients with stage I liver cancer based on competitive risk model and conditional survival rate.
     PLoS One. 2024;19:e0298014.
     PubMed     Abstract available
     
     
     
170. AZAMAR-LLAMAS D, Arenas-Martinez JS, Olivas-Martinez A, Jimenez JV, et al
     Impact of COVID-19 vaccination on liver transplant recipients. Experience in a reference center in Mexico.
     PLoS One. 2024;19:e0301198.
     PubMed     Abstract available
     
     
     
171. RAN S, Song L, Yang H, Yu J, et al
     Piperine alleviates nonalcoholic steatohepatitis by inhibiting NF-kappaB-mediated hepatocyte pyroptosis.
     PLoS One. 2024;19:e0301133.
     PubMed     Abstract available
     
     
     
172. WILSON EA, Woodbury A, Williams KM, Coopersmith CM, et al
     OXIDATIVE study: A pilot prospective observational cohort study protocol examining the influence of peri-reperfusion hyperoxemia and immune dysregulation on early allograft dysfunction after orthotopic liver transplantation.
     PLoS One. 2024;19:e0301281.
     PubMed     Abstract available
     
     
     
173. ZHANG H, Cheng X, Guo W, Zheng C, et al
     Metastasis patterns and prognosis in young gastric cancer patients: A propensity score?matched SEER database analysis.
     PLoS One. 2024;19:e0301834.
     PubMed     Abstract available
     
     
     
174. STAUFFER WT, Bobardt M, Ure DR, Foster RT, et al
     Cyclophilin D knockout significantly prevents HCC development in a streptozotocin-induced mouse model of diabetes-linked NASH.
     PLoS One. 2024;19:e0301711.
     PubMed     Abstract available
     
     
     
175. GABUZA K, Mabuda TI, Patel O, Khuboni N, et al
     Afriplex GRTTM extract attenuates hepatic steatosis in an in vitro model of NAFLD.
     PLoS One. 2024;19:e0297572.
     PubMed     Abstract available
     
     
     
176. WU T, Yang H, Li J, Fang H, et al
     Jolkinolide B inhibits the progression of hepatocellular carcinoma by regulating Musashi-2 protein.
     PLoS One. 2024;19:e0299920.
     PubMed     Abstract available
     
     
     
177. CHAVEZ-TAPIA NC, Sanchez-Jimenez BA, Vidana-Perez D, Corrales-Rosas B, et al
     Predictors for liver fibrosis in non-alcoholic patients with psoriatic diseases: A multicenter cross sectional-study.
     PLoS One. 2024;19:e0290632.
     PubMed     Abstract available
     
     
     
178. GURUN M, Brennan P, Handjiev S, Khatib A, et al
     Increased risk of chronic kidney disease and mortality in a cohort of people diagnosed with metabolic dysfunction associated steatotic liver disease with hepatic fibrosis.
     PLoS One. 2024;19:e0299507.
     PubMed     Abstract available
     
     
     
179. BAEK M, Kim M, Choi HI, Binas B, et al
     Identification of differentially expressed mRNA/lncRNA modules in acutely regorafenib-treated sorafenib-resistant Huh7 hepatocellular carcinoma cells.
     PLoS One. 2024;19:e0301663.
     PubMed     Abstract available
     
     
     
180. PASTROVIC F, Novak R, Grgurevic I, Hrkac S, et al
     Serum proteomic profiling of patients with compensated advanced chronic liver disease with and without clinically significant portal hypertension.
     PLoS One. 2024;19:e0301416.
     PubMed     Abstract available
     
     
     
181. ADORINI L, Rigbolt K, Feigh M, Roth J, et al
     Increased hepatoprotective effects of the novel farnesoid X receptor agonist INT-787 versus obeticholic acid in a mouse model of nonalcoholic steatohepatitis.
     PLoS One. 2024;19:e0300809.
     PubMed     Abstract available
     
     
     
182. JI Z, Zhang C, Yuan J, He Q, et al
     Predicting the immunity landscape and prognosis with an NCLs signature in liver hepatocellular carcinoma.
     PLoS One. 2024;19:e0298775.
     PubMed     Abstract available
     
     
     
183. SUN J, Yang S, Zhang Y, Xiang W, et al
     Relationship between phthalates exposures and metabolic dysfunction-associated fatty liver disease in United States adults.
     PLoS One. 2024;19:e0301097.
     PubMed     Abstract available
     
     
     
184. SMITH K, Beach D, Silva R, Balazs G, et al
     Comprehensive analysis of differentially expressed miRNAs in hepatocellular carcinoma: Prognostic, predictive significance and pathway insights.
     PLoS One. 2024;19:e0296198.
     PubMed     Abstract available
     
     
     
185. LIU XH, Chen HK, Luo J, He XP, et al
     Potassium affects the association between dietary intake of vitamin C and NAFLD among adults in the United States.
     PLoS One. 2024;19:e0295986.
     PubMed     Abstract available
     
     
     
186. LIU L, Zhang M, Cui N, Liu W, et al
     Integration of single-cell RNA-seq and bulk RNA-seq to construct liver hepatocellular carcinoma stem cell signatures to explore their impact on patient prognosis and treatment.
     PLoS One. 2024;19:e0298004.
     PubMed     Abstract available
     
     
     
187. LI N, Jin S, Wu J, Ji H, et al
     Effect of different treatment modalities on ovarian cancer patients with liver metastases: A retrospective cohort study based on SEER.
     PLoS One. 2024;19:e0299504.
     PubMed     Abstract available
     
     
     
188. LIN YH, Zhang ZJ, Zhong JQ, Wang ZY, et al
     Semaglutide combined with empagliflozin vs. monotherapy for non-alcoholic fatty liver disease in type 2 diabetes: Study protocol for a randomized clinical trial.
     PLoS One. 2024;19:e0302155.
     PubMed     Abstract available
     
     
     
189. BI CQ, Kang T, Qian YK, Kang M, et al
     Upregulation of LHPP by saRNA inhibited hepatocellular cancer cell proliferation and xenograft tumor growth.
     PLoS One. 2024;19:e0299522.
     PubMed     Abstract available
     
     
     
190. BENGTSSON B, Maucourant C, Sandberg JK, Bjorkstrom NK, et al
     Evaluation of mucosal-associated invariant T-cells as a potential biomarker to predict infection risk in liver cirrhosis.
     PLoS One. 2024;19:e0294695.
     PubMed     Abstract available
     
     
     
191. YAMABA S, Imai Y, Sugawara K, Uchida Y, et al
     Usefulness of atezolizumab plus bevacizumab as second-line therapy for patients with unresectable hepatocellular carcinoma.
     PLoS One. 2024;19:e0298770.
     PubMed     Abstract available
     
     
     
192. PAN Z, Bayoumi A, Metwally M, George J, et al
     Exportin 4 DNA promoter methylation in liver fibrosis.
     PLoS One. 2024;19:e0302786.
     PubMed     Abstract available
     
     
     
193. TABACU L, Swami S, Ledbetter M, Siddiqui MS, et al
     Socioeconomic status and health disparities drive differences in accelerometer-derived physical activity in fatty liver disease and significant fibrosis.
     PLoS One. 2024;19:e0301774.
     PubMed     Abstract available
     
     
     
194. YUAN C, Li W, Liu J, Li J, et al
     Frailty and transplant-free survival of patients with liver cirrhosis: A meta-analysis.
     PLoS One. 2024;19:e0302836.
     PubMed     Abstract available
     
     
     
195. GALIERO R, Loffredo G, Simeon V, Caturano A, et al
     Impact of liver fibrosis on COVID-19 in-hospital mortality in Southern Italy.
     PLoS One. 2024;19:e0296495.
     PubMed     Abstract available
     
     
     
196. FUNUYET-SALAS J, Martin-Rodriguez A, Perez-San-Gregorio MA, Vale L, et al
     Health-related quality of life in non-alcoholic fatty liver disease: A cross-cultural study between Spain and the United Kingdom.
     PLoS One. 2024;19:e0300362.
     PubMed     Abstract available
     
     
     
197. VATSYAYAN A, Kumar M, Saikia BJ, Scaria V, et al
     WilsonGenAI a deep learning approach to classify pathogenic variants in Wilson Disease.
     PLoS One. 2024;19:e0303787.
     PubMed     Abstract available
     
     
     
198. OSAWA Y, Kawai H, Nakashima K, Nakaseko Y, et al
     Sphingosine-1-phosphate promotes liver fibrosis in metabolic dysfunction-associated steatohepatitis.
     PLoS One. 2024;19:e0303296.
     PubMed     Abstract available
     
     
     
199. BAN JY, Kang TW, Jeong WK, Lee MW, et al
     Value of Sonazoid-enhanced ultrasonography in characterizing indeterminate focal liver lesions on gadoxetic acid-enhanced liver MRI in patients without risk factors for hepatocellular carcinoma.
     PLoS One. 2024;19:e0304352.
     PubMed     Abstract available
     
     
     
200. CHU YH, Pang BY, Yang M, Meng Q, et al
     The intervention of curcumin on rodent models of hepatic fibrosis: A systematic review and meta-analysis.
     PLoS One. 2024;19:e0304176.
     PubMed     Abstract available
     
     
     
201. TARU MG, Tefas C, Neamti L, Minciuna I, et al
     FAST and Agile-the MASLD drift: Validation of Agile 3+, Agile 4 and FAST scores in 246 biopsy-proven NAFLD patients meeting MASLD criteria of prevalent caucasian origin.
     PLoS One. 2024;19:e0303971.
     PubMed     Abstract available
     
     
     
202. POSCHEL T, Blank V, Schlosser T, Lingscheidt T, et al
     Ultrasound-guided percutaneous biopsy for focal liver lesions: Adverse events and diagnostic yield in a single-centre analysis.
     PLoS One. 2024;19:e0304026.
     PubMed     Abstract available
     
     
     
203. SHEN Y, Fan J, Liu S, Tao L, et al
     Exploring pathogenesis and biomarkers through establishment of a rat model of male infertility with liver depression and kidney deficiency.
     PLoS One. 2024;19:e0303189.
     PubMed     Abstract available
     
     
     
204. WEN C, Zhang X, Li Y, Xiao W, et al
     An interpretable machine learning model for predicting 28-day mortality in patients with sepsis-associated liver injury.
     PLoS One. 2024;19:e0303469.
     PubMed     Abstract available
     
     
     
205. MORENO J, Gluud LL, Galsgaard ED, Hvid H, et al
     Identification of ligand and receptor interactions in CKD and MASH through the integration of single cell and spatial transcriptomics.
     PLoS One. 2024;19:e0302853.
     PubMed     Abstract available
     
     
     
206. DONG X, Deng Y, Chen G
     Selenium intake in relation to all-cause and cardiovascular mortality in individuals with nonalcoholic fatty liver disease: A nationwide study in nutrition.
     PLoS One. 2024;19:e0303140.
     PubMed     Abstract available
     
     
     
207. SHI H, Xu H, Huang S, Tan Z, et al
     Gender disparity between first and senior authors on liver cancer research in the top journals of Gastroenterology and Hepatology.
     PLoS One. 2024;19:e0295648.
     PubMed     Abstract available
     
     
     
208. LU J, Feng Y, Guo K, Sun L, et al
     Association between human blood metabolome and the risk of gastrointestinal tumors.
     PLoS One. 2024;19:e0304574.
     PubMed     Abstract available
     
     
     
209. HUANG X, Gu H, Shen P, Zhang X, et al
     Systematic review and meta-analysis: Evaluating the influence of intrahepatic cholestasis of pregnancy on obstetric and neonatal outcomes.
     PLoS One. 2024;19:e0304604.
     PubMed     Abstract available
     
     
     
210. PENG T, Duong KS, Lu JY, Chacko KR, et al
     Incidence, characteristics, and risk factors of new liver disorders 3.5 years post COVID-19 pandemic in the Montefiore Health System in Bronx.
     PLoS One. 2024;19:e0303151.
     PubMed     Abstract available
     
     
     
211. PFISTERER N, Schwarz M, Schwarz C, Putre F, et al
     Statins, metformin, and RAS inhibitors did not reduce variceal bleeding risk and mortality in a large, real-life cohort of patients with cirrhosis.
     PLoS One. 2024;19:e0302811.
     PubMed     Abstract available
     
     
     
212. WANG F, Gan J, Li R, Yang R, et al
     Naringin from Ganshuang granule inhibits inflammatory to relieve liver fibrosis through TGF-beta-Smad signaling pathway.
     PLoS One. 2024;19:e0304185.
     PubMed     Abstract available
     
     
     
213. ZHANG R, Li S, Schippers K, Eimers B, et al
     Unraveling the impact of AXIN1 mutations on HCC development: Insights from CRISPR/Cas9 repaired AXIN1-mutant liver cancer cell lines.
     PLoS One. 2024;19:e0304607.
     PubMed     Abstract available
     
     
     
214. FARIA RM, Rosa SSRF, Nunes GAMA, Santos KS, et al
     Particle swarm optimization solution for roll-off control in radiofrequency ablation of liver tumors: Optimal search for PID controller tuning.
     PLoS One. 2024;19:e0300445.
     PubMed     Abstract available
     
     
     
215. LIU G, Zhang Q, Zhou M, Li B, et al
     Correlation between serum uric acid to high-density lipoprotein cholesterol ratio and atrial fibrillation in patients with NAFLD.
     PLoS One. 2024;19:e0305952.
     PubMed     Abstract available
     
     
     
216. PAUKNER M, Ladner DP, Zhao L
     Dynamic risk prediction of survival in liver cirrhosis: A comparison of landmarking approaches.
     PLoS One. 2024;19:e0306328.
     PubMed     Abstract available
     
     
     
217. YANG X, Liao Y, Fan L, Lin B, et al
     High-intensity focused ultrasound ablation combined with immunotherapy for treating liver metastases: A prospective non-randomized trial.
     PLoS One. 2024;19:e0306595.
     PubMed     Abstract available
     
     
     
218. 
     Expression of Concern: The Antimetastatic Effects of Resveratrol on Hepatocellular Carcinoma through the Downregulation of a Metastasis-Associated Protease by SP-1 Modulation.
     PLoS One. 2024;19:e0306742.
     PubMed    
     
     
     
219. MATSUBARA K, Kuroda S, Kobayashi T, Ide K, et al
     Feasibility, safety, and efficacy of intraoperative magnetic resonance imaging-guided hepatectomy for small hepatocellular carcinoma: A retrospective study.
     PLoS One. 2024;19:e0306307.
     PubMed     Abstract available
     
     
     
220. CHANG JJ, Lin T, Jhang XY, Chan SP, et al
     hnRNP Q/SYNCRIP interacts with LIN28B and modulates the LIN28B/let-7 axis in human hepatoma cells.
     PLoS One. 2024;19:e0304947.
     PubMed     Abstract available
     
     
     
221. ZHANG XF, Qin YY
     Association between SII and markers of liver injury: A cross-sectional study from the NHANES (2017-2020).
     PLoS One. 2024;19:e0303398.
     PubMed     Abstract available
     
     
     
222. WANG Y, Lau W, Li Y, Tian Y, et al
     Efficacy comparison of immune combination therapies in subgroups for advanced hepatocellular carcinoma patients: Systematic review and network meta-analysis.
     PLoS One. 2024;19:e0306869.
     PubMed     Abstract available
     
     
     
223. ABDELKHALIK M, Al Tawil S, El Fouani A, Allakiss N, et al
     Unveiling metabolic dysfunction-associated fatty liver disease: Knowledge gaps and attitudes among Lebanese university students.
     PLoS One. 2024;19:e0306825.
     PubMed     Abstract available
     
     
     
224. MA W, Liu R, Wang J, Liu L, et al
     High tumor burden score indicated the unfavorable prognosis in patients with hepatocellular carcinoma: A meta-analysis.
     PLoS One. 2024;19:e0308570.
     PubMed     Abstract available
     
     
     
225. MORIHARA H, Yamada T, Tona Y, Akasaka M, et al
     Anti-CTLA-4 treatment suppresses hepatocellular carcinoma growth through Th1-mediated cell cycle arrest and apoptosis.
     PLoS One. 2024;19:e0305984.
     PubMed     Abstract available
     
     
     
226. QUITETE FT, Teixeira AVS, Peixoto TC, Martins BC, et al
     Long-term exposure to polychlorinated biphenyl 126 induces liver fibrosis and upregulates miR-155 and miR-34a in C57BL/6 mice.
     PLoS One. 2024;19:e0308334.
     PubMed     Abstract available
     
     
     
227. DU PISANIE JL, Ramakrishnan V, Patel V, Commander C, et al
     MRI paraspinous skeletal muscle enhancement: A potential imaging biomarker for assessing clinical liver cirrhosis severity.
     PLoS One. 2024;19:e0308520.
     PubMed     Abstract available
     
     
     
228. KATSUMI T, Sato H, Murakami R, Hanatani T, et al
     Identification of microbial antigens in liver tissues involved in the pathogenesis of primary biliary cholangitis using 16S rRNA metagenome analysis.
     PLoS One. 2024;19:e0308912.
     PubMed     Abstract available
     
     
     
229. WOOLLEY JJ, Fishman J, Parrinello CM, O'Connell T, et al
     Cardiovascular risk in US adults with nonalcoholic steatohepatitis (NASH) vs. matched non-NASH controls, National Health and Nutrition Examination Survey, 2017-2020.
     PLoS One. 2024;19:e0309617.
     PubMed     Abstract available
     
     
     
230. LAI GS, Chen CS, Cheng JC, Li JR, et al
     Impact of different visceral metastatic sites on survival in metastatic prostate cancer patients.
     PLoS One. 2024;19:e0309941.
     PubMed     Abstract available
     
     
     
231. PAN K, Wang S, Li X, Wu S, et al
     Efficacy and safety of ultrasound-guided radiofrequency ablation combined with transhepatic artery embolization chemotherapy for hepatocellular carcinoma: A meta-analysis.
     PLoS One. 2024;19:e0305965.
     PubMed     Abstract available
     
     
     
232. YANG X, Xia L, Shen C, Li J, et al
     Curcumin alleviates heatstroke-induced liver injury in dry-heat environments by inhibiting the expression of NF-kappaB, iNOS, and ICAM-1 in rats.
     PLoS One. 2024;19:e0309598.
     PubMed     Abstract available
     
     
     
233. GUO R, Yu K, Huang K, Li J, et al
     Regulatory mechanism of Sarmentosin and Quercetin on lipid accumulation in primary hepatocyte of GIFT tilapia (Oreochromis niloticus) with fatty liver.
     PLoS One. 2024;19:e0309976.
     PubMed     Abstract available
     
     
     
234. ADRA S, Alabrach Y, Hashem A, Mahmoud A, et al
     Trends of primary liver cancer incidence and mortality in the United States: A population-based study over the last four decades.
     PLoS One. 2024;19:e0309465.
     PubMed     Abstract available
     
     
     
235. PAIK JM, Shah D, Eberly K, Golabi P, et al
     Changes in mortality due to Chronic Liver Diseases (CLD) during the COVID-19 pandemic: Data from the United States' National Vital Statistics System.
     PLoS One. 2024;19:e0289202.
     PubMed     Abstract available
     
     
     
236. SEPEHRINEZHAD A, Moghaddam NG, Shayan N, Sahab Negah S, et al
     Correlation of ammonia and blood laboratory parameters with hepatic encephalopathy: A systematic review and meta-analysis.
     PLoS One. 2024;19:e0307899.
     PubMed     Abstract available
     
     
     
237. XUE H, Liu Y, Liu Y, Li H, et al
     Myosteatosis and the clinical outcomes of patients with liver cirrhosis: A meta-analysis.
     PLoS One. 2024;19:e0310017.
     PubMed     Abstract available
     
     
     
238. MAKARY MS, Alexander J, Regalado LE, Jalil S, et al
     Clinical outcomes of DEB-TACE in locally advanced hepatocellular carcinoma: A 5-year real world experience.
     PLoS One. 2024;19:e0309693.
     PubMed     Abstract available
     
     
     
239. WATAD H, Ohayon A, Meyer R, Cohen A, et al
     Proteinuria is a clinical characteristic of intrahepatic cholestasis of pregnancy but it is not a marker of severity: A retrospective cohort study.
     PLoS One. 2024;19:e0310217.
     PubMed     Abstract available
     
     
     
240. MONTAGNON E, Cerny M, Hamilton V, Derennes T, et al
     Radiomics analysis of baseline computed tomography to predict oncological outcomes in patients treated for resectable colorectal cancer liver metastasis.
     PLoS One. 2024;19:e0307815.
     PubMed     Abstract available
     
     
     
241. CAI K, Fang Y, Zhang Y, Liu J, et al
     Cetylpyridinium chloride inhibits hepatocellular carcinoma growth and metastasis through regulating epithelial-mesenchymal transition and apoptosis.
     PLoS One. 2024;19:e0310391.
     PubMed     Abstract available
     
     
     
242. IBRAHIM A, Guha S, Lu L, Geng P, et al
     The reproducibility and predictivity of radiomic features extracted from dynamic contrast-enhanced computed tomography of hepatocellular carcinoma.
     PLoS One. 2024;19:e0310486.
     PubMed     Abstract available
     
     
     
243. FORLANO R, Stanic T, Jayawardana S, Mullish BH, et al
     Derivation and validation of the BIMAST score for predicting the presence of fibrosis due to Metabolic dysfunction-associated steatotic liver disease among diabetic patients in the community.
     PLoS One. 2024;19:e0307500.
     PubMed     Abstract available
     
     
     
244. SAEKI I, Shimose S, Tomonari T, Ito T, et al
     Alpha-fetoprotein and des-gamma-carboxy prothrombin can predict the objective response of patients with hepatocellular carcinoma receiving durvalumab plus tremelimumab therapy.
     PLoS One. 2024;19:e0311084.
     PubMed     Abstract available
     
     
     
245. ZHU X, Mo M, Zheng S, Han K, et al
     Comparing the prognosis of esophageal adenocarcinoma with bone and liver metastases: A competing risk analysis.
     PLoS One. 2024;19:e0303842.
     PubMed     Abstract available
     
     
     
246. XIONG Y, Zheng Y, Long W, Wang Y, et al
     Study on microwave ablation temperature prediction model based on grayscale ultrasound texture and machine learning.
     PLoS One. 2024;19:e0308968.
     PubMed     Abstract available
     
     
     
247. MAIORANA F, Neschuk M, Caronia MV, Elizondo K, et al
     The interplay between Helicobacter pylori infection and rs738409 PNPLA3 in metabolic dysfunction-associated steatotic liver disease.
     PLoS One. 2024;19:e0310361.
     PubMed     Abstract available
     
     
     
248. HE X, Liu F, Gong Q
     Identification of a senescence-related transcriptional signature to uncover molecular subtypes and key genes in hepatocellular carcinoma.
     PLoS One. 2024;19:e0311696.
     PubMed     Abstract available
     
     
     
249. ALY SH, Mahmoud AMA, Abdel Mageed SS, Khaleel EF, et al
     Exploring the phytochemicals, antioxidant properties, and hepatoprotective potential of Moricandia sinaica leaves against paracetamol-induced toxicity: Biological evaluations and in Silico insights.
     PLoS One. 2024;19:e0307901.
     PubMed     Abstract available
     
     
     
250. BAO S, Li S, Sun Y
     Hederagenin regulates the migration and invasion of hepatocellular carcinoma cells through FOXO signaling pathway.
     PLoS One. 2024;19:e0310930.
     PubMed     Abstract available
     
     
     
251. OHKAWA K, Nakabori T, Mukai K, Kozumi K, et al
     Clinical validation of the suppressive impact of letrozole on liver fibrosis in patients with breast cancer undergoing continuous letrozole administration: A retrospective study.
     PLoS One. 2024;19:e0311930.
     PubMed     Abstract available
     
     
     
252. MOHAMMED OA, Youssef ME, Hamad RS, Abdel-Reheim MA, et al
     Unlocking vinpocetine's oncostatic potential in early-stage hepatocellular carcinoma: A new approach to oncogenic modulation by a nootropic drug.
     PLoS One. 2024;19:e0312572.
     PubMed     Abstract available
     
     
     
253. CHUNG HJ, Seo N, Han K, Bae H, et al
     Gadoxetic acid-enhanced MRI for the detection of liver metastases from melanoma.
     PLoS One. 2024;19:e0313212.
     PubMed     Abstract available
     
     
     
254. HANNA DH, Al-Atmani AK, AlRashidi AA, Shafee EE, et al
     Camellia sinensis methanolic leaves extract: Phytochemical analysis and anticancer activity against human liver cancer cells.
     PLoS One. 2024;19:e0309795.
     PubMed     Abstract available
     
     
     
255. YAMANE A, Yasui D, Itoh H, Kobayashi M, et al
     An experimental study on the diagnostic advantage of dual-energy computed tomography over single-energy scan to evaluate the treatment effect following transcatheter arterial chemoembolization.
     PLoS One. 2024;19:e0313543.
     PubMed     Abstract available
     
     
     
256. PORTO-BARBOSA T, Ramos LF, Pansa CC, Molica LR, et al
     Inhibition of the miR-1914-5p increases the oxidative metabolism in cellular model of steatosis by modulating the Sirt1-PGC-1alpha pathway and systemic cellular activity.
     PLoS One. 2024;19:e0313185.
     PubMed     Abstract available
     
     
     
257. RUAN C, Wang C, Gu J, Zhu Z, et al
     Isoscopoletin inhibits hepatocellular carcinoma cell proliferation via regulating glycolysis-related proteins.
     PLoS One. 2024;19:e0310530.
     PubMed     Abstract available
     
     
     
258. LUO Y, Guo C, Ling C, Yu W, et al
     Pine pollen reverses the function of hepatocellular carcinoma by inhibiting alpha-Enolase mediated PI3K/AKT signaling pathway.
     PLoS One. 2024;19:e0312434.
     PubMed     Abstract available
     
     
     
259. CHAVAN S, McRae MP, Pitts KR, Everson GT, et al
     Cost-effectiveness of an oral cholate challenge test for the management of patients at risk for large esophageal varices.
     PLoS One. 2024;19:e0313006.
     PubMed     Abstract available
     
     
     
260. YU HB, Hu JQ, Han BJ, Du YY, et al
     Combinatorial treatment with traditional medicinal preparations and VEGFR-tyrosine kinase inhibitors for middle-advanced primary liver cancer: A systematic review and meta-analysis.
     PLoS One. 2024;19:e0313443.
     PubMed     Abstract available
     
     
     
261. DONG J, Li Z, Wang C, Zhang R, et al
     Dietary folate intake and all-cause mortality and cardiovascular mortality in American adults with non-alcoholic fatty liver disease: Data from NHANES 2003 to 2018.
     PLoS One. 2024;19:e0314148.
     PubMed     Abstract available
     
     
     
262. PILLING D, Martinez TC, Gomer RH
     Inhibition of CCl4-induced liver inflammation and fibrosis by a NEU3 inhibitor.
     PLoS One. 2024;19:e0308060.
     PubMed     Abstract available
     
     
     
263. WONG CR, Crespi CM, Glenn B, Han SB, et al
     Distinct risk groups with different healthcare barriers and acute care use exist in the U.S. population with chronic liver disease.
     PLoS One. 2024;19:e0311077.
     PubMed     Abstract available
     
     
     
264. PAN X, Lv J, Liu M, Li Y, et al
     Chronic systemic inflammation predicts long-term mortality among patients with fatty liver disease: Data from the National Health and Nutrition Examination Survey 2007-2018.
     PLoS One. 2024;19:e0312877.
     PubMed     Abstract available
     
     
     
265. NAIRZ J, Messner A, Kiechl SJ, Winder B, et al
     Prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD) and its association with arterial stiffness in adolescents: Results from the EVA4YOU study.
     PLoS One. 2024;19:e0314585.
     PubMed     Abstract available
     
     
     
266. ZHONG Q, Zhao B, She X, Liu X, et al
     HMGA2 as a prognostic and immune biomarker in hepatocellular carcinoma: Comprehensive analysis of the HMG family and experiments validation.
     PLoS One. 2024;19:e0311204.
     PubMed     Abstract available
     
     
     
267. FUKUMOTO M, Miyamoto D, Soyama A, Hara T, et al
     Characteristics of chemically induced liver progenitors derived from a pig model of metabolic dysfunction-associated steatotic liver disease.
     PLoS One. 2024;19:e0313312.
     PubMed     Abstract available
     
     
     
268. LIAO J, Wang H, Gu H, Cai Y, et al
     Liver tumor segmentation method combining multi-axis attention and conditional generative adversarial networks.
     PLoS One. 2024;19:e0312105.
     PubMed     Abstract available
     
     
     
269. YOO J, Lee JM, Joo I, Yoon JH, et al
     Contrast vector imaging for differential diagnosis of focal liver lesions: Analysis of tumoral vascular structures and flow characteristics.
     PLoS One. 2024;19:e0314263.
     PubMed     Abstract available
     
     
     
270. ZHANG Y, Lu L, Chen M, Nie J, et al
     Identification and validation of ATP6V1G1-regulated phosphorylated proteins in hepatocellular carcinoma.
     PLoS One. 2024;19:e0310037.
     PubMed     Abstract available
     
     
     
271. WANG S, Lu K, Lin L, Li G, et al
     Exploring the mechanism of berberine treatment for atherosclerosis combined with non-alcoholic fatty liver disease based on bioinformatic and experimental study.
     PLoS One. 2024;19:e0314961.
     PubMed     Abstract available
     
     
     
272. KOMATSU K, Sano K, Fukai K, Nakagawa R, et al
     Standardized evaluation of diabetic retinopathy using artificial intelligence and its association with metabolic dysfunction-associated steatotic liver disease in Japan: A cross-sectional study.
     PLoS One. 2024;19:e0315752.
     PubMed     Abstract available
     
     
     
273. HUYBRECHTS I, Jacobs I, Biessy C, Aglago EK, et al
     Associations between dietary mycotoxins exposures and risk of hepatocellular carcinoma in a European cohort.
     PLoS One. 2024;19:e0315561.
     PubMed     Abstract available
     
     
     
274. ZHANG S, Xu Q, Liu C, Wu Z, et al
     Management and prognostic prediction of pyogenic liver abscess in a Chinese tertiary hospital: Percutaneous needle aspiration vs catheter drainage.
     PLoS One. 2024;19:e0315371.
     PubMed     Abstract available
     
     
     
275. SMITH MR, Yu EL, Malki GJ, Newton KP, et al
     Systematic review of exercise for the treatment of pediatric metabolic dysfunction-associated steatotic liver disease.
     PLoS One. 2024;19:e0314542.
     PubMed     Abstract available
     
     
     
276. HUANG T, Chen H, Pan H, Wu T, et al
     Comprehensive analysis of bioinformatics and system biology reveals the association between Girdin and hepatocellular carcinoma.
     PLoS One. 2024;19:e0315534.
     PubMed     Abstract available
     
     
     
277. CAO W, Pan X, Jin L, Liu J, et al
     Construction of reusable fluorescent assembled 3D-printed hydrogen-based models to simulate minimally invasive resection of complex liver cancer.
     PLoS One. 2024;19:e0316199.
     PubMed     Abstract available
     
     
     
278. WEJNARUEMARN S, Suksawatamnuay S, Vanichanan J, Komolmit P, et al
     Association between serum endocan levels and organ failure in hospitalized patients with cirrhosis.
     PLoS One. 2024;19:e0315619.
     PubMed     Abstract available
     
     
     
279. GUO W, Weng T, Song Y
     Association of serum selenium with MASLD and liver fibrosis: A cross-sectional study.
     PLoS One. 2024;19:e0314780.
     PubMed     Abstract available
     
     
     
280. JOSHI V, Carter D, Chen AE, Murphy K, et al
     Induction of MASH in three-dimensional bioprinted human liver tissue.
     PLoS One. 2024;19:e0312615.
     PubMed     Abstract available
     
     
     January 2023
281. HE Z, Shen X, Wang B, Xu L, et al
     CT radiomics for noninvasively predicting NQO1 expression levels in hepatocellular carcinoma.
     PLoS One. 2023;18:e0290900.
     PubMed     Abstract available
     
     
     
282. HEERKENS L, van Kleef LA, de Knegt RJ, Voortman T, et al
     Fatty Liver Index and mortality after myocardial infarction: A prospective analysis in the Alpha Omega Cohort.
     PLoS One. 2023;18:e0287467.
     PubMed     Abstract available
     
     
     
283. FENG Q, Lu H, Wu L
     Identification of M2-like macrophage-related signature for predicting the prognosis, ecosystem and immunotherapy response in hepatocellular carcinoma.
     PLoS One. 2023;18:e0291645.
     PubMed     Abstract available
     
     
     
284. SCHMIDT U, Uluca B, Vokic I, Malik B, et al
     Inducible overexpression of a FAM3C/ILEI transgene has pleiotropic effects with shortened life span, liver fibrosis and anemia in mice.
     PLoS One. 2023;18:e0286256.
     PubMed     Abstract available
     
     
     
285. TITHI TI, Tahsin MR, Anjum J, Zaman TS, et al
     An in vivo and in silico evaluation of the hepatoprotective potential of Gynura procumbens: A promising agent for combating hepatotoxicity.
     PLoS One. 2023;18:e0291125.
     PubMed     Abstract available
     
     
     
286. HINTZEN KFH, Eussen MMM, Neutel C, Bouvy ND, et al
     A systematic review on the detection of volatile organic compounds in exhaled breath in experimental animals in the context of gastrointestinal and hepatic diseases.
     PLoS One. 2023;18:e0291636.
     PubMed     Abstract available
     
     
     
287. NAGAI K, Tamura M, Murayama R, Fukuno S, et al
     Development of multi-drug resistance to anticancer drugs in HepG2 cells due to MRP2 upregulation on exposure to menthol.
     PLoS One. 2023;18:e0291822.
     PubMed     Abstract available
     
     
     
288. BEER S, Babel J, Martin N, Blank V, et al
     Non-invasive assessment of steatohepatitis indicates increased risk of coronary artery disease.
     PLoS One. 2023;18:e0286882.
     PubMed     Abstract available
     
     
     
289. HUANG Q, Guo J, Zhao H, Zheng Y, et al
     The associations of alcoholic liver disease and nonalcoholic fatty liver disease with bone mineral density and the mediation of serum 25-Hydroxyvitamin D: A bidirectional and two-step Mendelian randomization.
     PLoS One. 2023;18:e0292881.
     PubMed     Abstract available
     
     
     
290. CHAKRABARTY D, Wang K, Roy G, Bhojgaria A, et al
     Constructing training set using distance between learnt graphical models of time series data on patient physiology, to predict disease scores.
     PLoS One. 2023;18:e0292404.
     PubMed     Abstract available
     
     
     
291. PHAM HN, Pham L, Sato K
     Bioinformatic analysis identified novel candidate genes with the potentials for diagnostic blood testing of primary biliary cholangitis.
     PLoS One. 2023;18:e0292998.
     PubMed     Abstract available
     
     
     
292. TAN Z, Zhang J, Xu L, Wang H, et al
     Triple combination of HAIC-FO plus tyrosine kinase inhibitors and immune checkpoint inhibitors for advanced hepatocellular carcinoma: A systematic review and meta-analysis.
     PLoS One. 2023;18:e0290644.
     PubMed     Abstract available
     
     
     
293. CHACON C, Arteaga I, Martinez-Escude A, Ruiz Rojano I, et al
     Clinical epidemiology of non-alcoholic fatty liver disease in children and adolescents. The LiverKids: Study protocol.
     PLoS One. 2023;18:e0286586.
     PubMed     Abstract available
     
     
     
294. NAGAKAWA K, Hidaka M, Hara T, Matsushima H, et al
     Serum wisteria floribunda agglutinin-positive human Mac-2 binding protein is unsuitable as a diagnostic marker of occult hepatocellular carcinoma in end-stage liver cirrhosis.
     PLoS One. 2023;18:e0293593.
     PubMed     Abstract available
     
     
     
295. ANTWI MB, Dumitriu G, Simon-Santamaria J, Romano JS, et al
     Liver sinusoidal endothelial cells show reduced scavenger function and downregulation of Fc gamma receptor IIb, yet maintain a preserved fenestration in the Glmpgt/gt mouse model of slowly progressing liver fibrosis.
     PLoS One. 2023;18:e0293526.
     PubMed     Abstract available
     
     
     
296. CHIHARA K, Okada K, Uchida F, Miura I, et al
     Macrophage specific restoration of the Nrf2 gene in whole-body knockout mice ameliorates steatohepatitis induced by lipopolysaccharide from Porphyromonas gingivalis through enhanced hepatic clearance.
     PLoS One. 2023;18:e0291880.
     PubMed     Abstract available
     
     
     
297. RIENECK K, Rasmussen KK, Schoof EM, Clausen FB, et al
     Hunting for the elusive target antigen in gestational alloimmune liver disease (GALD).
     PLoS One. 2023;18:e0286432.
     PubMed     Abstract available
     
     
     
298. SPOONER MH, Garcia-Jaramillo M, Apperson KD, Lohr CV, et al
     Time course of western diet (WD) induced nonalcoholic steatohepatitis (NASH) in female and male Ldlr-/- mice.
     PLoS One. 2023;18:e0292432.
     PubMed     Abstract available
     
     
     
299. PARK SS, Mai M, Ploszaj M, Cai H, et al
     Type 1 diabetes contributes to combined pulmonary fibrosis and emphysema in male alpha 1 antitrypsin deficient mice.
     PLoS One. 2023;18:e0291948.
     PubMed     Abstract available
     
     
     
300. CABARCAS-PETROSKI S, Olshefsky G, Schramm L
     MAF1 is a predictive biomarker in HER2 positive breast cancer.
     PLoS One. 2023;18:e0291549.
     PubMed     Abstract available
     
     
     
301. ARSHAD U, Zenobi MG, Tribulo P, Staples CR, et al
     Dose-dependent effects of rumen-protected choline on hepatic metabolism during induction of fatty liver in dry pregnant dairy cows.
     PLoS One. 2023;18:e0290562.
     PubMed     Abstract available
     
     
     
302. ZOU H, Xue Y, Chen X, Lai Y, et al
     Comparative analysis of disease modelling for health economic evaluations of systemic therapies in advanced hepatocellular carcinoma.
     PLoS One. 2023;18:e0292239.
     PubMed     Abstract available
     
     
     
303. HAYASHI H, Shimizu A, Kubota K, Notake T, et al
     Impact of sarcopenic obesity on post-hepatectomy bile leakage for hepatocellular carcinoma.
     PLoS One. 2023;18:e0286353.
     PubMed     Abstract available
     
     
     
304. YANG H, Meng L, Xin S, Chang C, et al
     Non-linear association between aspartate aminotransferase to alanine aminotransferase ratio and mortality in critically ill older patients: A retrospective cohort study.
     PLoS One. 2023;18:e0293749.
     PubMed     Abstract available
     
     
     
305. MOON JJ, Hong SK, Kim YC, Hong SY, et al
     Soluble suppression of tumorigenicity 2 is a potential predictor of post-liver transplant renal outcomes.
     PLoS One. 2023;18:e0293844.
     PubMed     Abstract available
     
     
     
306. OEHM AW, Zablotski Y, Hoedemaker M, Campe A, et al
     Associations of production characteristics with the on-farm presence of Fasciola hepatica in dairy cows vary across production levels and indicate differences between breeds.
     PLoS One. 2023;18:e0294601.
     PubMed     Abstract available
     
     
     
307. YEN YH, Kuo FY, Eng HL, Liu YW, et al
     Tumor necrosis as a predictor of early tumor recurrence after resection in patients with hepatoma.
     PLoS One. 2023;18:e0292144.
     PubMed     Abstract available
     
     
     
308. SONG W, Yan X, Zhai Y, Ren J, et al
     Probiotics attenuate valproate-induced liver steatosis and oxidative stress in mice.
     PLoS One. 2023;18:e0294363.
     PubMed     Abstract available
     
     
     
309. AIN NAZIR NU, Shaukat MH, Luo R, Abbas SR, et al
     Novel breath biomarkers identification for early detection of hepatocellular carcinoma and cirrhosis using ML tools and GCMS.
     PLoS One. 2023;18:e0287465.
     PubMed     Abstract available
     
     
     
310. LIU K, Hu S, Qiu L, Wang M, et al
     Nrf1 is not a direct target gene of SREBP1, albeit both are integrated into the rapamycin-responsive regulatory network in human hepatoma cells.
     PLoS One. 2023;18:e0294508.
     PubMed     Abstract available
     
     
     
311. JUNG C, Park S, Kim H
     Association between hypoglycemic agent use and the risk of occurrence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus.
     PLoS One. 2023;18:e0294423.
     PubMed     Abstract available
     
     
     
312. TATEAI Y, Kawakami K, Teramae M, Fukuda N, et al
     Factors associated with lenvatinib adherence in thyroid cancer and hepatocellular carcinoma.
     PLoS One. 2023;18:e0294320.
     PubMed     Abstract available
     
     
     
313. CHO BS, Fligor SC, Fell GL, Secor JD, et al
     A medium-chain fatty acid analogue prevents hepatosteatosis and decreases inflammatory lipid metabolites in a murine model of parenteral nutrition-induced hepatosteatosis.
     PLoS One. 2023;18:e0295244.
     PubMed     Abstract available
     
     
     
314. QIU B, Liang JX, Romero Gomez M
     The efficacy and safety of granulocyte colony-stimulating factor in the treatment of acute-on-chronic liver failure: A systematic review and meta-analysis.
     PLoS One. 2023;18:e0294818.
     PubMed     Abstract available
     
     
     
315. BITTER EE, Skidmore J, Allen CI, Erickson RI, et al
     TK1 expression influences pathogenicity by cell cycle progression, cellular migration, and cellular survival in HCC 1806 breast cancer cells.
     PLoS One. 2023;18:e0293128.
     PubMed     Abstract available
     
     
     
316. IIZASA S, Nagao K, Tsuge K, Nagano Y, et al
     Identification of genes regulated by lipids from seaweed Susabinori (Pyropia yezoensis) involved in the improvement of hepatic steatosis: Insights from RNA-Seq analysis in obese db/db mice.
     PLoS One. 2023;18:e0295591.
     PubMed     Abstract available
     
     
     
317. OEHM AW, Zablotski Y, Campe A, Hoedemaker M, et al
     Random forest classification as a tool in epidemiological modelling: Identification of farm-specific characteristics relevant for the occurrence of Fasciola hepatica on German dairy farms.
     PLoS One. 2023;18:e0296093.
     PubMed     Abstract available
     
     
     
318. MOUNIKA N, Yadav A, Kamboj P, Banerjee SK, et al
     Circulatory bone morphogenetic protein (BMP) 8B is a non-invasive predictive biomarker for the diagnosis of non-alcoholic steatohepatitis (NASH).
     PLoS One. 2023;18:e0295839.
     PubMed     Abstract available
     
     
     
319. GUO Y, Chen Y, Zhang Y, Xu M, et al
     Recombinant human adenovirus p53 combined with transcatheter arterial chemoembolization for liver cancer: A meta-analysis.
     PLoS One. 2023;18:e0295323.
     PubMed     Abstract available
     
     
     
320. PORUKALA M, Vinod PK
     Gene expression signatures of stepwise progression of Hepatocellular Carcinoma.
     PLoS One. 2023;18:e0296454.
     PubMed     Abstract available
     
     
     
321. PELOSO A, Lacotte S, Gex Q, Slits F, et al
     Portosystemic shunting prevents hepatocellular carcinoma in non-alcoholic fatty liver disease mouse models.
     PLoS One. 2023;18:e0296265.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Liver Diseases is free of charge.